View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.

Accreditation/ Credit Designation

The University of Cincinnati and Physicians’ Education Resource®, LLC, are both accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians, and have collaborated to design and execute this enduring educational activity.

For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of participation for this activity.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.

For further information concerning Lilly grant funding, visit

Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize Outcomes

Release Date: August 16, 2017
Expiration Date: August 16, 2018
Media: Internet - based


Activity Overview

Are you prepared to provide state-of-the-art care to the next patient who presents to your clinic with a soft tissue sarcoma (STS)? Don’t miss this opportunity to hear renowned experts discuss the current standard of care and provide insights into the evolving approaches and breakthroughs occurring in the field of STS.

Historically poor outcomes in patients with metastatic STS have led to therapeutic nihilism among some physicians. However, a greater appreciation of the heterogeneous, complex biologies across the many STS subtypes, as well as the development of new and emerging therapeutic approaches, are transforming the ways in which these malignancies are managed. Optimal treatment requires a highly skilled, multidisciplinary team that encompasses medicine, pathology, radiology, and surgery.

Join us to learn about what’s on the horizon for STS and to gain up-to-date guidance on the delivery of cross-discipline care for patients with STS that leverages the resources of both community- and academic-based healthcare providers.

CME Activity Table of Contents

  • Module 1: Optimization of Molecular Diagnostic Techniques in Light of New Targets and New Options
  • Module 2: Choosing First-Line Therapy: Key Questions Driving Treatment Decisions
  • Module 3: Therapy for Recurrent Soft Tissue Sarcoma
  • Module 4: Evolving Data and Approaches to Immuno-oncology for Sarcomas

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists, as well as fellows, who manage patients with STS. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with STS may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Detail methods to engage community-based oncologists to communicate with sarcoma specialists in the care of patients with STS in multiple lines of treatment
  2. Evaluate clinical circumstances that impact sequencing decision making along the disease continuum in the management of STS
  3. Explain disease heterogeneity in advanced STS, and its impact on treatment strategies and methods to overcome challenges to optimize diagnoses in the field
  4. Describe novel mechanistic approaches that have been applied to the treatment of patients with metastatic or unresectable STS

Faculty, Staff, and Planners' Disclosures


George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosure: Grant Research Support: Bayer, Novartis, Pfizer, Janssen Oncology (research support from these commercial interests to Dana-Farber for GD as PI in clinical trial agreements in DFCI Sarcoma unit).

Robin L. Jones, BSc, MB, MRCP, MD (Res)
Consultant Oncologist and Head of Sarcoma Unit
Royal Marsden Hospital
Team Leader, Sarcoma Clinical Trials
Institute of Cancer Research
London, England

Disclosure: No relevant financial relationships with commercial interests.

William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Consultant: Blueprint Medicines, Immune Design, Eisai Inc., Eli Lilly and Company, Janssen Pharmaceutical, EMD Serono, Inc., and Novartis.

Sandra P. D’Angelo, MD
Assistant Attending Physician
Sarcoma Medical Oncology/Immunotherapeutics Core
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Consultant: Nektar Therapeutics, EMD, Serono/Pfizer, and Amgen.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its cme activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a cme activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This cme activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this cme activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME Provider Contact Information

Technical Support: For technical questions related to this activity or issues with your CME Certificate, please contact:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Accreditation Support: Please contact:
University of Cincinnati Continuing Medical Education
PO Box 670556
Cincinnati, OH 45267

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Calendar of Events
Filter By